The General Clinical research Center at the State University of New York/Downstate Medical Center provides inpatient and outpatient facilities for clinical research studies in man, both adult and pediatric patients may participate in clinical research studies on the GCRC. The GCRC Core laboratory includes a special laboratory for assays of prostaglandins and related metabolites of arachidonic acid and other polyunsaturated fatty acids in biological fluids. These assays are available to all clinical investigators who require such studies as a part of approved human research progocols utilizing the GCRC. The Core laboratory provides facilities for balance studies and processes specimens from biological fluids for forwarding to other laboratories. Many recently activated GCRC protocols involve studies of glucose metabolism and metabolic bone disease. The GCRC core laboratory is developing a number of new procedures to support these new studies. Protocols which utilize the GCRC core prostaglin laboratory include: Studies of Intestinal Hormones; Humoral Mediators of the Dumping Syndrome; Regulation of Gastric Acid Secretion by Prostaglandins; Pathogenesis and Management of Diabetes Mellitus. Recently approved clinical studies include: Abnormalities of the Hypothalamic-Pituitary-Adrenal Axis in Patients with Acquired Immune Deficiency Syndrome; Phase I Trial of CL 246,738 in Patients with Acquired Immune Deficiency Syndrome; Relationship of Gastroesophageal Reflux to Chronic Asthma in Children and Adults; Treatment of Dialysis Osteomalacia with 24,25 Dihydroxycholecalciferol; Multiple Dose Evaluation of McN 3935 in Patients with Type II Diabetes Mellitus; Insulin Sensitivity in Depressed Patients with Hypersecretion of Cortisol. These along with ongoing studies such as: Vulnerability of the Reproductive System to Stress; Phosphate Binding Antacid Therapy for Secondary Hyperparathyroidism; Combined Insulin Sulfonylurea Therapy in Type II Diabetes; and Plasma Osteocalcin Levels in Metabolic Bone Disease are representative of the types of research activities which we anticipate for the current year.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000318-24
Application #
3089921
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
1975-10-01
Project End
1992-11-30
Budget Start
1989-12-01
Budget End
1990-11-30
Support Year
24
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Suny Downstate Medical Center
Department
Type
Schools of Medicine
DUNS #
068552207
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Brehm, John M; Ramratnam, Sima K; Tse, Sze Man et al. (2015) Stress and Bronchodilator Response in Children with Asthma. Am J Respir Crit Care Med 192:47-56
Chaiken, R L; Eckert-Norton, M; Bard, M et al. (1998) Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Diabetes Care 21:2129-34
Banerji, M A; Chaiken, R L; Lebovitz, H E (1996) Long-term normoglycemic remission in black newly diagnosed NIDDM subjects. Diabetes 45:337-41
Brunicardi, F C; Chaiken, R L; Ryan, A S et al. (1996) Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 81:3566-72
Chaiken, R L; Palmisano, J; Norton, M E et al. (1995) Interaction of hypertension and diabetes on renal function in black NIDDM subjects. Kidney Int 47:1697-702
Banerji, M A; Chaiken, R L; Lebovitz, H E (1995) Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 44:466-70
Banerji, M A; Buckley, M C; Chaiken, R L et al. (1995) Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 19:846-50
Banerji, M A; Chaiken, R L; Gordon, D et al. (1995) Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 44:141-6
Chaiken, R L; Eckert-Norton, M; Pasmantier, R et al. (1995) Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 38:1307-12
Banerji, M A; Chaiken, R L; Huey, H et al. (1994) GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes. Diabetes 43:741-5

Showing the most recent 10 out of 31 publications